Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response’s only substantive label-related claim (contraindication in personal/family history of MTC or MEN 2 due to thyroid C-cell tumor risk) is explicitly supported by OZEMPIC Sections 4 and 5.1 and is consistent with nonclinical findings in Section 13.1. No contradictions were identified.
Category Scores
Accurate Statements
OZEMPIC (semaglutide) is contraindicated in patients with a personal or family history of medullary thyroid cancer (MTC) or in patients with MEN 2 due to a risk of thyroid C-cell tumors described in the label.
Supported by OZEMPIC Section 4 CONTRAINDICATIONS (contraindication for personal/family history of MTC or MEN 2) and Section 5.1 Risk of Thyroid C-Cell Tumors (dose- and treatment-duration-dependent thyroid C-cell tumor findings in rodents; human relevance unknown). Consistent with nonclinical findings in Section 13.1.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim is a direct contraindication from the label; no unsafe or contradictory statements were made relative to the provided prescribing information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
No issues identified for the evaluated contraindication-related claim.
Suggested Improvement